Manifold Partners’s Stemline Therapeutics, Inc. STML Stock Holding History

Manifold Partners’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q4	–	Sell	-950	Closed	-$43K	–	150
2013 Q3	$43K	Sell	950 -1,000	-51%	-$32.6K	0.03%	83
2013 Q2	$46K	Buy	+1,950	New	+$31.1K	0.03%	87

Other funds holding STML

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

SCA

SAC Capital Advisors Stamford, Connecticut $19.3B AUM 31.93% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RCI

Ridgeback Capital Investments Miami Beach, Florida $80.9M AUM

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Manifold Partners's STML Position: Q4 2013 in Review

Manifold Partners sold out of Stemline Therapeutics, Inc. (STML) in Q4 2013, closing a stake of 950 shares — an estimated $43K sold.

Manifold Partners first reported a position in STML in Q2 2013 and held it in 2 quarters. The position peaked at $46K in Q2 2013. 69 funds tracked by Wall St. Rank hold STML as of Q4 2013.

Manifold Partners reported no remaining Stemline Therapeutics, Inc. position as of Q4 2013 after selling out during the quarter.
Manifold Partners sold 950 Stemline Therapeutics, Inc. shares in Q4 2013, an estimated $43K.
Manifold Partners first reported a position in Stemline Therapeutics, Inc. in Q2 2013 and held it in 2 quarters.
Manifold Partners's Stemline Therapeutics, Inc. position peaked at $46K in Q2 2013.
69 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q4 2013.

Based on Manifold Partners's 13F filing for Q4 2013, filed 27 Jan 2014.